Ipilimumab

Drug Profile

Ipilimumab

Alternative Names: BMS-734016; MDX 101; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Brain metastases; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Adrenal cancer; Liver cancer; Lung cancer; Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 22 Dec 2016 Bristol-Myers Squibb plans the phase II CheckMate 592 trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, First-line therapy) in USA (IV) (NCT03001882)
  • 16 Dec 2016 Bristol Myers-Squibb plans a phase III trial for Non-small cell lung cancer in USA, Argentina, Brazil, Canada, France, Hungary, Ireland, Italy, the Netherlands, Romania, Spain, South Africa, Turkey and United Kingdom (NCT02998528) (EudraCT2016-003536-21)
  • 06 Dec 2016 Interim efficacy and safety data from a phase I/II CheckMate-032 trial in small cell lung cancer released by Bristol-Myers Squibb Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top